Qun Tian

Guangxi Key Laboratory Of Clinical Disease Biotechnology Research
Liuzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

An Interpretable Machine Learning Model for Predicting the Presence of Talaromycosis in HIV Patients Lacking Skin Lesions.

An Interpretable Machine Learning Model for Predicting the Presence of Talaromycosis in HIV Patients Lacking Skin Lesions.

Journal: Mycopathologia

Published: August 23, 2025

Prevalence of isolated cryptococcal antigenemia and efficacy of preemptive fluconazole treatment in people living with HIV: A multicenter, retrospective cohort study in China.

Prevalence of isolated cryptococcal antigenemia and efficacy of preemptive fluconazole treatment in people living with HIV: A multicenter, retrospective cohort study in China.

Journal: Chinese medical journal

Published: April 20, 2025

Severe anemia, severe leukopenia, and severe thrombocytopenia of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated talaromycosis: a subgroup analysis of a prospective multicenter cohort study.

Severe anemia, severe leukopenia, and severe thrombocytopenia of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated talaromycosis: a subgroup analysis of a prospective multicenter cohort study.

Journal: BMC infectious diseases

Published: August 19, 2022

Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China.

Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China.

Journal: Infectious diseases and therapy

Published: March 23, 2022

Initiating antiretroviral therapy within 2 weeks of anti-Pneumocystis treatment does not increase mortality or AIDS-defining events in patients with HIV-associated moderate to severe Pneumocystis pneumonia: results of a prospective observational multicenter study.

Initiating antiretroviral therapy within 2 weeks of anti-Pneumocystis treatment does not increase mortality or AIDS-defining events in patients with HIV-associated moderate to severe Pneumocystis pneumonia: results of a prospective observational multicenter study.

Journal: BMC pulmonary medicine

Published: December 11, 2021

HIV-associated talaromycosis: Does timing of antiretroviral therapy matter?

HIV-associated talaromycosis: Does timing of antiretroviral therapy matter?

Journal: The Journal of infection

Published: September 17, 2021

Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection.

Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection.

Journal: HIV medicine

Published: October 12, 2020

Multicentre derivation and validation of a prognostic scoring system for mortality assessment in HIV-infected patients with talaromycosis.

Multicentre derivation and validation of a prognostic scoring system for mortality assessment in HIV-infected patients with talaromycosis.

Journal: Mycoses

Published: July 08, 2020

Showing 1-8 of 8

Last Updated: 09/26/2026